Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Syon Capital LLC

Syon Capital LLC increased its position in Becton, Dickinson and Company (NYSE:BDX) by 40.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,867 shares of the medical instruments supplier’s stock after acquiring an additional 542 shares during the period. Syon Capital LLC’s holdings in Becton, Dickinson and Company were worth $455,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. OFI Invest Asset Management purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Fortitude Family Office LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $35,000. Venturi Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 552.0% in the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 138 shares during the last quarter. Arlington Trust Co LLC purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $41,000. Finally, MCF Advisors LLC boosted its stake in Becton, Dickinson and Company by 51.4% in the 4th quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock worth $52,000 after buying an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $231.55 on Friday. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The firm has a market capitalization of $66.89 billion, a PE ratio of 54.87, a P/E/G ratio of 1.90 and a beta of 0.43. The company’s 50 day simple moving average is $239.24 and its 200 day simple moving average is $241.42. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. During the same quarter in the prior year, the firm earned $2.98 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on BDX shares. Raymond James lifted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Barclays increased their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.